The Oligonucleotide-based Therapeutics Summit is uniting leaders in RNA chemistry, delivery science, and translational biology to advance oligonucleotides as a pioneering therapeutic class.

With multiple approvals, growing clinical validation across diverse indications, and breakthroughs in chemical modifications and delivery platforms, oligonucleotides are no longer a niche field, they’re rapidly becoming the modality of choice for tackling both validated and previously “undruggable” targets. The question is no longer if oligonucleotides will reshape the therapeutic landscape, but how fast.

This December in Boston, unite with leading experts from Secarna, Genentech, Avidity Bioscience, Dyne Therapeutics, Biogen, Novo Nordisk, Stoke Therapeutics, and more as they reveal cutting-edge insights spanning discovery to late-stage development. Discover how advances in RNA chemistry and delivery are unlocking safer, more precise therapies, broadening therapeutic potential, and driving faster patient impact. Don’t miss the only meeting dedicated exclusively to unlocking the full therapeutic potential of oligonucleotides.